Editas Medicine, Inc. (EDIT) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
8.75
↑+200% vs avg
5yr avg: 2.92
30Y Low0.8·High10.4
ROE
↓
-198.1%
↑-131% vs avg
5yr avg: -85.7%
30Y Low-377%·High-35%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
EDIT Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Editas Medicine, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $263M | $182M | $105M | $770M | $609M | $1.8B | $4.1B | $1.5B | $1.1B | $1.2B | $523M |
| Enterprise Value | $193M | $112M | $8M | $694M | $511M | $1.6B | $4.0B | $1.3B | $969M | $1.1B | $373M |
| P/E Ratio → | -1.49 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 6.50 | 4.49 | 3.24 | 9.85 | 30.90 | 70.28 | 45.29 | 72.09 | 33.55 | 90.26 | 86.39 |
| P/B Ratio | 8.75 | 6.67 | 0.78 | 2.20 | 1.69 | 3.24 | 10.44 | 5.64 | 4.54 | 5.96 | 3.88 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
EDIT EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.76 | 0.25 | 8.89 | 25.95 | 63.35 | 44.04 | 61.90 | 30.34 | 82.02 | 61.57 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
EDIT Profitability
Margins and return-on-capital ratios measuring operating efficiency
Editas Medicine, Inc. earns an operating margin of -245.2%. Operating margins have compressed from -216.6% to -245.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -198.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 92.2% | 67.9% | 80.2% | -74.1% | -372.0% | -183.9% | -505.8% | -841.3% |
| Operating Margin | -245.2% | -245.2% | -777.2% | -216.6% | -1146.3% | -756.1% | -148.6% | -686.4% | -356.1% | -873.6% | -1605.6% |
| Net Profit Margin | -395.0% | -395.0% | -733.7% | -196.1% | -1118.3% | -753.6% | -127.8% | -651.4% | -344.3% | -876.5% | -1605.5% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -198.1% | -198.1% | -98.1% | -43.2% | -48.2% | -40.6% | -35.4% | -53.6% | -49.5% | -70.2% | -377.5% |
| ROA | -60.6% | -60.6% | -56.4% | -30.2% | -37.0% | -30.8% | -21.4% | -28.8% | -27.7% | -39.9% | -51.3% |
| ROIC | — | — | -120.8% | -47.2% | -53.0% | -44.1% | -60.7% | -113.0% | -74.6% | -227.0% | — |
| ROCE | -49.1% | -49.1% | -71.7% | -38.0% | -41.7% | -33.7% | -28.0% | -33.8% | -31.5% | -45.0% | -57.4% |
EDIT Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $147M exceeds total debt of $77M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 2.81 | 2.81 | 0.26 | 0.14 | 0.12 | 0.05 | 0.07 | 0.11 | 0.14 | 0.16 | 0.26 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.56 | -0.72 | -0.22 | -0.27 | -0.32 | -0.29 | -0.80 | -0.43 | -0.54 | -1.12 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -24.94 | -24.94 | — | — | — | — | — | — | — | -122.03 | — |
Net cash position: cash ($147M) exceeds total debt ($77M)
EDIT Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Editas Medicine, Inc.'s current ratio of 3.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.39x to 3.54x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.44 | 9.05 | 5.66 |
| Quick Ratio | 3.54 | 3.54 | 3.75 | 5.39 | 5.94 | 10.82 | 7.20 | 7.74 | 10.36 | 9.00 | 5.61 |
| Cash Ratio | 3.17 | 3.17 | 3.50 | 5.11 | 5.73 | 10.66 | 6.91 | 7.62 | 10.28 | 8.97 | 5.60 |
| Asset Turnover | — | 0.22 | 0.09 | 0.16 | 0.04 | 0.04 | 0.16 | 0.04 | 0.08 | 0.04 | 0.03 |
| Inventory Turnover | — | — | — | — | — | — | — | — | 31.07 | 44.61 | 34.28 |
| Days Sales Outstanding | — | 136.70 | 183.73 | 47.59 | 95.27 | 3.82 | 24.33 | 7.43 | 0.34 | 18.05 | 5.31 |
EDIT Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Editas Medicine, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $89M | $82M | $76M | $69M | $68M | $59M | $50M | $47M | $40M | $32M |
Peer Comparison
Compare EDIT with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 EDITYou | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
 BEAM | $4B | -42.1 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 SGMO | $75M | -0.4 | — | — | 80.8% | -273.1% | -2891.8% | -5405.6% | — |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 ACMR | $7B | 80.2 | 54.2 | — | 44.4% | 12.1% | 6.2% | 7.0% | 2.4 |
 ILMN | $25B | 29.7 | 22.7 | 26.4 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $173B | 26.2 | 18.7 | 27.4 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
 REGN | $63B | 14.7 | 15.3 | 15.5 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
EDIT — Frequently Asked Questions
Quick answers to the most common questions about buying EDIT stock.
What is Editas Medicine, Inc.'s P/E ratio?
Editas Medicine, Inc.'s current P/E ratio is -1.5x. This places it at the 50th percentile of its historical range.
What is Editas Medicine, Inc.'s ROE?
Editas Medicine, Inc.'s return on equity (ROE) is -198.1%. The historical average is -101.4%.
Is EDIT stock overvalued?
Based on historical data, Editas Medicine, Inc. is trading at a P/E of -1.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Editas Medicine, Inc.'s profit margins?
Editas Medicine, Inc. has 100.0% gross margin and -245.2% operating margin.